GRITSTONE ONCOLOGY INC's ticker is GRTS and the CUSIP is 39868T105. A total of 62 filers reported holding GRITSTONE ONCOLOGY INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $75,339 | -8.5% | 43,802 | +3.7% | 0.00% | -100.0% |
| Q2 2023 | $82,378 | -5.3% | 42,245 | +99.2% | 0.00% | – |
| Q1 2022 | $87,000 | -70.2% | 21,212 | -6.6% | 0.00% | -100.0% |
| Q4 2021 | $292,000 | +22.2% | 22,706 | +2.7% | 0.00% | 0.0% |
| Q3 2021 | $239,000 | +15.5% | 22,100 | -2.3% | 0.00% | 0.0% |
| Q2 2021 | $207,000 | +25.5% | 22,626 | +29.0% | 0.00% | 0.0% |
| Q1 2021 | $165,000 | +139.1% | 17,545 | +0.3% | 0.00% | – |
| Q4 2020 | $69,000 | +43.8% | 17,499 | -2.8% | 0.00% | – |
| Q3 2020 | $48,000 | -60.3% | 18,000 | -1.0% | 0.00% | -100.0% |
| Q2 2020 | $121,000 | +40.7% | 18,174 | +23.2% | 0.00% | – |
| Q1 2020 | $86,000 | -38.6% | 14,753 | -5.5% | 0.00% | -100.0% |
| Q4 2019 | $140,000 | +2.9% | 15,605 | -0.8% | 0.00% | 0.0% |
| Q3 2019 | $136,000 | -23.2% | 15,736 | -0.7% | 0.00% | 0.0% |
| Q2 2019 | $177,000 | +200.0% | 15,846 | +259.2% | 0.00% | – |
| Q1 2019 | $59,000 | -15.7% | 4,412 | -3.1% | 0.00% | – |
| Q4 2018 | $70,000 | – | 4,555 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,561,150 | $6,125,178 | 3.26% |
| Redmile Group, LLC | 8,509,126 | $14,635,697 | 0.70% |
| Avidity Partners Management LP | 2,733,800 | $4,702,136 | 0.19% |
| Frazier Life Sciences Management, L.P. | 1,430,878 | $2,461,110 | 0.16% |
| Artia Global Partners LP | 95,170 | $163,692 | 0.07% |
| Worth Venture Partners, LLC | 43,772 | $75,288 | 0.04% |
| SkyOak Wealth, LLC | 60,875 | $104,705 | 0.03% |
| Point72 Asset Management, L.P. | 5,924,867 | $10,190,771 | 0.03% |
| CORNERCAP INVESTMENT COUNSEL INC | 76,811 | $132,115 | 0.02% |
| Houlihan Financial Resource Group, Ltd. | 20,000 | $38 | 0.02% |